Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Clinical trial NCT00105092 · COMPLETED

Trial details

NCT number: NCT00105092
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small-Cell Lung Carcinoma

Start date: 2005-03-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.